Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Scientists Discover How Aging Drives Breast Cancer Spread

Aging promotes a RAGE-dependent increase in breast cancer metastasis.

PubMed2 min readAI-assisted summary
Editorial illustration for Aging promotes a RAGE-dependent increase in breast cancer metastasis.
Editorial illustration

Summary

Doctors have long known that breast cancer becomes more dangerous as people get older. However, the exact reasons why aging increases the risk of the disease spreading have remained a mystery. Part of the problem is that most laboratory research relies on young mice, which do not accurately reflect the biology of an older human body. Now, researchers have shown that an aging body actively encourages breast cancer metastasis, which is the process where cancer spreads to other organs.

The research points to a specific protein on the surface of cells called the Receptor for Advanced Glycation End-products, or RAGE for short. Think of RAGE as a cellular antenna. As the body ages, it naturally produces higher levels of specific trigger molecules in the bloodstream. When these molecules bind to the RAGE antenna, the receptor flips genetic switches in the tumor. This chain reaction increases inflammation, builds new blood vessels, and changes the surrounding tissue scaffolding, ultimately pushing cancer cells to invade the rest of the body.

In a promising twist, the researchers found that blocking either the RAGE antenna or its trigger molecules successfully stopped cancer cells from invading in laboratory mice. The team also looked at historical data from human breast cancer patients. They found that older patients with highly active RAGE networks generally faced poorer survival odds, suggesting this exact same process happens in humans.

Why it matters.

This discovery represents a major shift in how we might treat older breast cancer patients. Currently, treatments mostly focus on attacking the tumor itself. These findings suggest that modifying the aging environment around the tumor by blocking RAGE could be a powerful new way to stop cancer from spreading. Because metastasis is the leading cause of breast cancer mortality, finding new therapies that specifically protect older patients could eventually save countless lives.

However, it is important to remember that this research is still in its early stages. The current evidence relies heavily on animal models and looking back at past human medical records. Before doctors can offer RAGE-targeted drugs to patients, scientists will need to conduct rigorous clinical trials to prove that these therapies are both safe and effective in humans.

From the source

The story in numbers.

Preclinical mouse models utilized
Multiple
Specific RAGE ligands elevated in aged hosts
S100A8/9
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Scientists Discover How Aging Drives Breast Cancer Spread — Daily Strand